Mylan innovation and science
At Mylan, we have a long tradition of innovation.

In fact, we’ve invested more than $3 billion in R&D globally over the last five years. And whether we’re developing more affordable versions of insulins, biologics or respiratory therapies, better health for a better world is our goal.

Science Around the Clock in Multiple R&D Sites Worldwide

Two global R&D centers,

including one in
West Virginia

Ten tech-focused R&D sites,

including one in Texas
and one in Vermont

>3,000

R&D, clinical, medical and regulatory professionals worldwide

>4,000

patents filed globally

~1,800

products pending approval worldwide

Challenging the Status Quo

Mylan takes on challenges no one else will, developing innovative, cost-effective and patient-friendly treatments for diseases like cancer, diabetes, HIV/AIDS and more.

For example, lack of refrigeration once meant lack of access to certain antiretroviral (ARV) medicines for millions of HIV/AIDS patients in developing countries. Our scientists responded by making heat-stable formulations.

And Mylan's innovations go way beyond medicines. Our services and patient-support programs address a wide range of health issues.

Challenging the Status Quo

Mylan takes on challenges no one else will, developing innovative, cost-effective and patient-friendly treatments for diseases like cancer, diabetes, HIV/AIDS and more.

For example, lack of refrigeration once meant lack of access to certain antiretroviral (ARV) medicines for millions of HIV/AIDS patients in developing countries. Our scientists responded by making heat-stable formulations.

And Mylan's innovations go way beyond medicines. Our services and patient-support programs address a wide range of health issues.

Delivering Medicine the Way Patients Need It

From tablets and capsules, injectables and ointments to inhalers and transdermals – Mylan provides patients the medicine they need, the way they need it.

>75B

oral solid doses, such
as tablets and capsules in 2017

>500M

units of injectable medicines in 2017

~1.3B

units of complex products, such
as transdermal patches, topical
products and respiratory therapies in 2017

Data as of Q2 2018

Driving Access to Advanced Treatments

Mylan is known for producing “difficult-to-develop” medicines. Many are used to treat diseases like cancer, autoimmune disorders, chronic obstructive pulmonary disease (COPD) and diabetes.

Mylan has ~20 biosimilar and insulin analog products on the market or in development worldwide.